The rapid rise of GLP-1 weight loss drugs is reshaping more than waistlines. A side effect that many users didn't anticipate — hair loss — is now generating a new wave of demand in the hair treatment industry, and the opportunity is already being measured in billions of dollars.

About one in eight U.S. adults currently takes a GLP-1 drug, according to recent surveys. By 2030, the number of users is expected to reach 25 million, up from just 5 million in 2023. As the patient population swells, so does the number of people experiencing telogen effluvium — a temporary shedding of hair triggered by rapid weight loss, nutrient deficiencies, and the body's shock response. It's not the drug molecules themselves that cause the thinning, but the metabolic stress of losing weight quickly.

That distinction matters, because it means the hair loss is both predictable and reversible. And that predictable cycle is turning into a durable business opportunity for companies selling shampoos, serums, supplements, and scalp treatments. According to research cited by CNBC, the market for GLP-1-adjacent hair care products could be worth $1 billion — a figure that beauty industry analysts call a “category reset.”

The biology behind the shedding

Hair loss from weight loss isn't a new phenomenon. Crash diets and bariatric surgery have long carried the same risk. But GLP-1 drugs accelerate weight loss more aggressively than many traditional methods, and the prevalence is far higher. Patients often lose 10% to 20% of their body weight within a year, a rate that can push hair follicles into a resting phase.

One GLP-1 user described losing hair in clumps about a year after starting treatment. She had very thick hair before the drug, and the shedding came on gradually enough that she didn't connect it to the medication for months. Her story mirrors the pattern reported by dermatologists and captured in clinical data from Novo Nordisk and Eli Lilly.

Novo Nordisk, maker of Ozempic and Wegovy, acknowledged in a statement to CNBC that hair loss is an identified risk for its GLP-1 medications, reported more frequently among patients with the greatest weight loss. Eli Lilly, which makes Mounjaro and Zepbound, confirmed hair loss as a consequence of its drugs and said patient safety is the company's top priority. Both companies continue to monitor the safety profiles of their products, including hair loss reports.

The mechanism is straightforward: rapid calorie restriction, reduced protein intake, and the body's diversion of resources away from non-essential functions (like hair growth) to preserve vital organs. The shedding typically begins three to six months after starting the drug and can last several months before regrowth starts. For many users, the cycle repeats if they adjust their dosage or lose additional weight.

The beauty industry's response

Accenture's global beauty lead called hair loss “one of the most significant side effects that the beauty industry is currently watching.” As GLP-1 drugs become more accessible, the demand for products that address the cosmetic consequence is growing faster than the broader hair care market.

Beauty companies are already moving. Ulta Beauty reported seeing increased consumer interest in hair treatment products tied to GLP-1 use. Redken, a L'Oreal-owned brand, launched an entire hair treatment line specifically tested on GLP-1 users — a rare targeted move for a mass-market brand. Nutrafol, a supplement company that sells hair growth capsules, says it is seeing higher demand from people taking weight loss drugs. KeraFactor, a scalp health company, told CNBC that its direct-to-consumer business grew 100% year-over-year, driven largely by GLP-1 users.

All three examples reflect a shift in how the beauty industry approaches products. The pandemic already pushed consumers toward “clean,” clinical, and dermatologist-backed formulations. Skincare led that shift; now hair care is following the same playbook. Winning brands, according to analysts, will need to combine science-backed, clinically proven ingredients with the aesthetics and texture that consumers expect from premium beauty products.

Consumers are spending more and staying longer

GLP-1 users are a lucrative demographic. The source reported that these consumers spend about 30% more on beauty products than the average buyer. They are also highly motivated to address side effects that affect their appearance, and hair loss is one of the most visible and distressing.

What makes this opportunity especially attractive to brands is the time horizon. Hair growth treatments take months to show results. A user who starts a supplement or topical regimen today won't see noticeable improvement for at least three to six months, and often longer. That creates a subscription-like buying pattern and lowers churn. Once a customer commits to a product, they are likely to keep purchasing for a year or more before deciding whether it works.

Investors have noticed. Hundreds of millions of dollars are flowing into companies that focus on hair health, from supplement startups to dermatology-backed device makers. The combination of a large, growing, and high-spending customer base with a predictable, long-lasting consumption cycle is rare in beauty.

What's next for the market

The hair loss associated with GLP-1 drugs is temporary for most people. The user interviewed for the original story said her hair eventually grew back, but it took multiple products, several years, and a lot of trial and error. That timeline — recovery is possible, but slow and uneven — is precisely the dynamic that keeps customers buying.

A few open questions remain. Will the FDA or drug manufacturers begin including more explicit warnings or guidance on hair loss in prescribing information? Novo Nordisk and Eli Lilly are both monitoring the issue, but neither has announced specific programs to address it beyond general safety surveillance. The burden is currently on patients to seek out solutions from beauty companies rather than from their doctors.

Also uncertain is whether the demand will persist if GLP-1 usage plateaus or if the drugs themselves evolve to have fewer side effects. For now, the trajectory points up. With tens of millions of people projected to be on these medications by 2030, the hair treatment industry has found a growth driver that shows no signs of slowing.

The beauty business has always been good at turning problems into products. GLP-1 hair loss is just the latest example — and it might be one of the most lucrative.